Scientific Opinion on the substantiation of health claims related to alpha cylcodextrin and reduction of post prandial glycaemic responses (ID 856, 2926), maintenance or achievement of a normal body weight (ID 2925) pursuant to Article 13(1) of Regulation (EC) No 1924/2006

Abstract

Scientific Opinion on the substantiation of health claims related to alpha-cylcodextrin and reduction of post-prandial glycaemic responses (ID 856, 2926), maintenance or achievement of a normal body weight (ID 2925) pursuant to Article 13(1) of Regulation (ECSUMMARY Following a request from the European Commission, the Panel on Dietetic Products, Nutrition and Allergies was asked to provide a scientific opinion on a list of health claims pursuant to Article 13 of Regulation (EC) No 1924. This opinion addresses the scientific substantiation of health claims in relation to alpha-cyclodextrin and reduction of post-prandial glycaemic responses and maintenance or achievement of a normal body weight. The scientific substantiation is based on the information provided by the Member States in the consolidated list of Article 13 health claims and references that EFSA has received from Member States or directly from stakeholders.The food constituent that is subject of the health claim is alpha-cyclodextrin. The Panel considers that alpha-cyclodextrin is sufficiently characterised. Reduction of post-prandial glycaemic responsesThe claimed effect is "glucose homeostasis". The target population is assumed to be subjects willing to reduce their post-prandial glycaemic responses. The Panel assumes that the claimed effect refers to the reduction of post-prandial glycaemic and insulinaemic responses. The Panel considers that the reduction of post-prandial glycaemic responses may be a beneficial physiological effect.

Cyclodextrin in starchy foods

“…a-CD and not b-CD was selected for these experiments, because a-CD can also strongly interact with fatty components of food, such as fatty acids and triglycerides, further enhancing health benefits (Schmid et al, 2004) and has no advisable daily intake (ADI) limit as b-CD does (0.5 mg/kg body weight/day). In 2012, the European Food Safety Authority (EFSA) issued a scientific opinion on the health claims related to reduction of post-prandial glycaemic responses by a-CD suggesting to consume at least 5 g of a-CD to each 50 g of starch to achieve considerable effect (EFSA, 2012).…”